Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Upgraded by Wall Street Zen

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other analysts have also issued reports on BCYC. Zacks Research lowered Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Needham & Company LLC dropped their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Jefferies Financial Group restated a “buy” rating and set a $10.00 target price on shares of Bicycle Therapeutics in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $13.57.

Bicycle Therapeutics Price Performance

Shares of BCYC stock opened at $3.66 on Friday. The firm has a fifty day moving average of $3.83 and a 200-day moving average of $4.58. Bicycle Therapeutics has a 12-month low of $3.33 and a 12-month high of $8.48.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.25. The firm had revenue of $34.06 million during the quarter, compared to analysts’ expectations of $12.22 million. Bicycle Therapeutics had a negative return on equity of 25.40% and a negative net margin of 169.75%. Equities analysts predict that Bicycle Therapeutics will post -2.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BCYC. GAMMA Investing LLC raised its position in shares of Bicycle Therapeutics by 512.9% in the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock valued at $33,000 after buying an additional 6,447 shares in the last quarter. Royal Bank of Canada increased its stake in Bicycle Therapeutics by 35.5% during the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock worth $67,000 after acquiring an additional 3,788 shares during the period. Portland Investment Counsel Inc. bought a new position in Bicycle Therapeutics during the 2nd quarter worth $64,000. R Squared Ltd acquired a new position in Bicycle Therapeutics in the 1st quarter valued at $98,000. Finally, Vontobel Holding Ltd. lifted its position in shares of Bicycle Therapeutics by 15.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 23,000 shares of the company’s stock valued at $85,000 after acquiring an additional 3,000 shares during the period. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.